1. Scrip
  2. >>COVID-19

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Plus: Japan Passes Bill For Free Vaccines

 
• By Scrip Team

Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.  

Novartis_Building
Novartis' global headquarters in Basel, Switzerland. Molecular Partners is located in nearby Zurich-Schlieren. • Source: Shutterstock

Novartis is to collaborate with Molecular Partners to develop and potentially commercialize the Swiss biotech company’s anti-COVID-19 DARPin program, consisting of two therapeutic candidates, MP0420 and MP0423.

DARPins or designed ankyrin repeat proteins are genetically engineered antibody mimetic proteins

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.